Regulus Therapeutics (RGLS) Stock Forecast & Price Target

$1.54 +0.01 (+0.65%)

(As of 01:00 PM ET)

Regulus Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 6 Analyst Ratings

Sell
0

Hold
1

Buy
5

Based on 6 Wall Street analysts who have issued ratings for Regulus Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 1 has given a hold rating, and 5 have given a buy rating for RGLS.

Consensus Price Target

$10.80
601.30% Upside

According to the 6 analysts' twelve-month price targets for Regulus Therapeutics, the average price target is $10.80. The highest price target for RGLS is $28.00, while the lowest price target for RGLS is $3.00. The average price target represents a forecasted upside of 601.30% from the current price of $1.54.

Get the Latest News and Ratings for RGLS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Regulus Therapeutics and its competitors.

RGLS Analyst Ratings Over Time

Type	Current Forecast 12/25/23 to 12/24/24	1 Month Ago 11/25/23 to 11/24/24	3 Months Ago 9/26/23 to 9/25/24	1 Year Ago 12/25/22 to 12/25/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	2 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$10.80	$10.80	$10.80	$10.50
Forecasted Upside	601.30% Upside	634.69% Upside	579.25% Upside	701.53% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

Forced out of retirement by these trades (Ad)

You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed

Make sure to check out Gamma Pockets HERE while it’s still widely available

RGLS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RGLS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Regulus Therapeutics Stock vs. The Competition

Type	Regulus Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.83	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	622.46% Upside	25,626.32% Upside	14.28% Upside
News Sentiment Rating	Positive News See Recent RGLS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/11/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00	+580.27%
8/14/2024	Oppenheimer 3 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$7.00 ➝ $7.00	+369.80%
6/25/2024	Canaccord Genuity Group 1 of 5 stars		Boost Target	Buy ➝ Buy	$11.00 ➝ $28.00	+1,272.54%
3/18/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Schwartz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/18/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$6.00	+184.36%
3/13/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$2.00 ➝ $3.00	+27.66%
6/28/2023	500.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:41 PM ET.

RGLS Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Regulus Therapeutics is $10.80, with a high forecast of $28.00 and a low forecast of $3.00.
: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last twelve months. There is currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RGLS shares.
: According to analysts, Regulus Therapeutics's stock has a predicted upside of 601.30% based on their 12-month stock forecasts.
: Regulus Therapeutics has been rated by research analysts at HC Wainwright in the past 90 days.
: Analysts like Regulus Therapeutics more than other "medical" companies. The consensus rating score for Regulus Therapeutics is 2.83 while the average consensus rating score for "medical" companies is 2.81. Learn more on how RGLS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Grab This Altcoin Before Trump's Crypto Announcement (Ad)

Grab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.

Click here to check it out now

This page (NASDAQ:RGLS) was last updated on 12/24/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regulus Therapeutics (RGLS) Stock Forecast & Price Target